ResMed Inc. with ticker code (RMD) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $280.00 and $180.00 and has a mean target at $235.93. Given that the stocks previous close was at $239.00 this indicates there is a potential downside of -1.3%. The 50 day MA is $230.70 and the 200 moving average now moves to $201.65. The market cap for the company is 35.87B. Currently the stock stands at: $244.12 USD
The potential market cap would be $35,408,296,059 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 35.33, revenue per share of $31.87 and a 12.7% return on assets.
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
